CSI Market
Sign In | Register

Protara Therapeutics Inc (TARA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TARA quarterly Cash Flow →
Cash flow patterns shown here provide context for understanding Protara Therapeutics Inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
12 Months 		(Mar 31 2025) (Dec 31 2024) (Dec 31 2023) (Dec 31 2022)
Operating Activities
Income-17.78
Depreciation & amortization0.09
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.36
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Foreign Currency Remeasurement Gain Loss-
Increase Decrease In Operating Lease Rightofuse Assets-
Stockbased Compensation-
Amortization Of Discounts And Premiums Investments-0.19
Increase Decrease In Operating Lease Liability-0.30
Increase Decrease In Operating Lease Liability-0.30
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.00
Increase (Decrease) in Accounts Payable1.09
Increase (Decrease) in Accrued Liabilities-2.60
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.26
Other Working Capital-3.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.59
Discontinued operations0.00
Net Cash flow from Operating Activities-21.34
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities29.14
Payments to Acquire Marketable Securities-43.86
Real Estate Investments0.00
Proceeds From Maturity Of Marketable Debt Securities Availableforsale-
Proceeds From Redemption Of Marketable Debt Securities Availableforsale-
Proceeds From Maturity And Redemption Of Marketable Debt Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-14.72
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-48.46
Proceeds From Issuance Of Common Stock Under E S P P-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Proteon Private Placement Net Of Offering Costs-
Proceeds From Issuances Of Convertible Preferred Stock-
Proceeds From Underwriters Overallotment Option-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents50.40
Proceeds From Common Stock In Proteon Private Placement Net Of Offering Costs-
Proceeds From September Common Stock Net Of Offering Costs-
Proceeds From Issuance Of Private Placement Net Of Issuance Costs-
Payments Of Taxes Related To Net Share Settlement Of Restricted Stock Units-0.27
Proceeds From Public Offering Net Of Issuance Costs-
Public Offering Costs Paid-0.53
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.14
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-21.34
Total Cash Flow-34.92
4 historic quarters locked

Sign in to unlock the full Protara Therapeutics Inc cash flow history.

Sign In Create Free Account

About Protara Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-025433

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License